Carotech Inc. (Edison, NJ) has announced the results of a new study linking its tocopherol-tocotrienol complex to significant reductions in total and bad cholesterol levels.
Carotech Inc. (Edison, NJ) has announced the results of a new study linking its tocopherol-tocotrienol complex to significant reductions in total and bad cholesterol levels.
In a double-blind, placebo-controlled study, 32 subjects with high cholesterol levels supplemented with 300 mg of Tocomin Suprabio or placebo daily for six months. Fasting blood and vitamin E (tocotrienol and alpha-tocopherol) levels were checked at baseline and every four weeks.
By the fourth month of the study, the tocomin group had experienced significant reductions in both total and low-density lipoprotein (LDL) cholesterol. These reductions continued into the fifth and sixth months of supplementation, with LDL levels reduced by 12.8% and 17.3% respectively, compared to baseline.
The placebo group showed only “negligible changes” in cholesterol levels throughout the study.
Triglyceride and high-density lipoprotein (HDL) cholesterol levels saw no significant fluctuations in either group during the study.
Carotech Inc. vice president WH Leong attributed the study results to SubraBio’s unique self-emulsifying system.
“Since an increase in tocotrienols’ blood level brings about significant cholesterol reduction, it is therefore important to ensure consistent and increased absorption of tocotrienol,” said Leong. “The SupraBio self-emulsifying system is unique and guarantees an average of 250% increase in tocotrienol absorption and hence improves tocotrienol bioavailability for the various positive health effects reported including cholesterol reduction.”
Meta-analysis does not find increased risk of bleeding events from omega-3 PUFA consumption
July 8th 2024Researchers reviewed 11 studies and found that there was no difference in the incidence of bleeding events between patients receiving omega-3 PUFAs and those not receiving them. High dose EPA consumption was associated with an elevated but modest risk.
Recent review states that pentadecanoic acid may support cellular stability for better longevity
June 25th 2024According to the paper’s author, Stephanie Venn-Watson, DVM, MPH, deficiency in pentadecanoic acid of ≤0.2% total circulating fatty acids increases the risk of ferroptosis, which a type of cell death cause by the peroxidation of fragile fatty acids in cell membranes that combines with iron thus increasing reactive oxygen species, and disabling mitochondria.
Recent review makes the case for testing omega-3 fatty acid levels in humans
May 23rd 2024The article commissioned by The Global Organization for EPA and DHA Omega-3s (GOED) reviewed the state of omega-3 fatty acid testing, highlighting the value of testing and the commercially available options for diagnostic testing.
Epax launches concentrated oil that combines omegas 3, 9, and 11
May 10th 2024The blend of long-chain polyunsaturated fatty acids and long-chain monounsaturated fatty acids combines the heart and brain health benefits of omegas-3s with the skin and metabolic health benefits of omegas 9 and 11.